Lifelong viral infections can quietly alter the immune system, with effects that persist over the time. Viruses such as the ...

Researchers uncover that ALV-J boosts miR-155 to suppress TRAF3 and STAT1, weakening immune responses and promoting viral ...

Two therapies can be better than one for treating some cancers, concludes a Yale study published Oct. 22 in JCI Insight that ...

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

Hematopoietic reprogramming reflects the selective and evolutionarily conserved engagement of transcription factor networks that encode innate immune memory in long-lived stem cells.

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory ...

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of NI-18 ...

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust ...